Clinical trial researching therapy for bile duct cancer

Dr. Jonathan Hernandez

Jonathan Hernandez, M.D.

Cholangiocarcinoma is a cancer of the bile ducts, a network of tubes that connect the liver, gallbladder and small intestine. One way to treat such cancer is to deliver drugs directly to the liver itself. A clinical trial led by Jonathan Hernandez, M.D., Investigator in the Surgical Oncology Program, is researching a combination of immunotherapy and chemotherapy for liver-only cholangiocarcinoma (cancer that has occurred in the liver but has not spread elsewhere in the body). The trial will take place at the NIH Clinical Center in Bethesda, Maryland, and there is no cost for participation.

For more information, please contact Cathleen Hannah at (240) 858-7006 or identifier: NCT05286814

NCI Protocol ID: NCI000307

Official Title: Phase II Study Evaluating the Efficacy of M9241 in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer or Intrahepatic Cholangiocarcinoma

The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care. Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland.  

For more information on CCR clinical trials click here, and subscribe to have the latest CCR clinical trials sent directly to your inbox.

Posted on Mon, 10/17/2022